ECHA opened public consultation on the Draft 13th Recommendation to include four SVHCs in the REACH Authorisation List (Annex XIV)

ECHA published the Draft 13th Recommendation and opened a public consultation (2 Feb 2026 to 2 May 2026) on prioritising four SVHCs for potential inclusion in the REACH Authorisation List (Annex XIV): bumetrizole (UV-326), UV-329, triphenyl phosphate, and 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one. This consultation is a key step in the SVHC-to-authorisation pathway; affected companies should assess uses and consider submitting evidence on uses, alternatives, and socio-economic impacts.